From the Lane Fox Respiratory Unit (ZP), Respiratory & Critical Care Medicine (NH), Guy's and St Thomas' Foundation Trust and Kings College, London, UK; Centre of Human & Aerospace Physiological Sciences (SH), School of Biomedical and Health Sciences, Kings College, London, UK; National Institute of Health Research Comprehensive Biomedical Research Centre (NH), London, UK.
Dr. Hart has received speaker's fees from Phillips-Respironics and Fisher-Paykel, and unrestricted research grants from Phillips-Respironics, B&D Electromedical, Resmed, Fisher-Paykel, and Guy's and St Thomas Charity. The remaining authors have not disclosed any potential conflicts of interest.
For information regarding this article, E-mail: firstname.lastname@example.org
Understanding the trajectory of skeletal muscle loss, evaluating its relationship to the subsequent functional impairment, and understanding the underlying mechanisms of skeletal muscle wasting will provide goals for novel treatment strategies in the intensive care setting. A focused approach on the effect of critical illness on muscle morphology, muscle protein turnover, and the associated muscle-signaling pathways during the early and recovery stages of critical illness is required. This could potentially lead to targeted pharmacologic and nonpharmacologic strategies to treat, or even prevent, peripheral muscle wasting and weakness.